Focus will be on Phase II to Phase IV studies.

GVK Biosciences and Excel PharmaStudies are combining their contract research services pertaining to clinical trials throughout India and China. Under the agreement, the two companies will help sponsors conduct and manage Phase II-IV studies, statistical analysis, and medical writing in both countries.

Each company will have access to the clinical research team and resources of the other company. Excel, based in China, will have India trials carried out by the GVK research team operating under a core management team from Excel. Similarly, a GVK trial in China will use an Excel research team overseen by GVK project managers.

The alliance reportedly allows the two companies access to the strengths both countries have to offer. India has sponsor-friendly regulations and a strong infrastructure for conducting Phase II and Phase III trials. China has a large market, making it a good candidate for Phase III and postmarketing Phase IV studies.

Previous articleStimulus Package for VCs Supporting Small Biotechs
Next articleMerck & Co. Gains Rights to Santen’s Glaucoma Drug in the Americas, W. Europe, and Africa